Adenylate cyclase 7/AC7/ADCY7 CRISPR/Cas9 KO Plasmid (h): sc-403213

Overview

ADCY7 encodes adenylate cyclase 7 (AC7), a membrane-associated enzyme that converts ATP to cyclic AMP, a second messenger that controls protein kinase A and EPAC signaling, transcriptional programs, and feedback regulation of immune and inflammatory responses. AC7 is engaged downstream of G protein–coupled receptors via Gαs and is modulated by Gβγ and other regulatory inputs, shaping stimulus-specific cAMP dynamics. In human cells, ADCY7-dependent cAMP signaling influences cytokine production, leukocyte activation, and cellular stress responses, linking this node to pathways relevant to inflammation and host defense. Genetic variation or altered regulation of cAMP-generating enzymes has been associated with susceptibility to inflammatory and metabolic phenotypes, supporting mechanistic studies of AC7 in disease-relevant cellular contexts.

Adenylate cyclase 7/AC7/ADCY7 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ADCY7 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ADCY7 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ADCY7 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Adenylate cyclase 7/AC7/ADCY7 protein expression.

This CRISPR knockout system enables efficient generation of ADCY7-deficient cell models for investigation of Adenylate cyclase 7/AC7/ADCY7 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

Key Features

• sgRNAs targeting ADCY7 exon(s) critical for Adenylate cyclase 7/AC7/ADCY7 function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• GFP reporter for identification of transfected cells
• Pool of plasmids targeting multiple ADCY7 genomic sites to improve knockout efficiency
• Compatible with delivery by transfection

Design Variants

CRISPRs +/- HDRs

• gRNAs encoded by Adenylate cyclase 7/AC7/ADCY7 CRISPR/Cas9 KO Plasmid (h) and Adenylate cyclase 7/AC7/ADCY7 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ADCY7 locus. One or both targeting designs may be available. See Related Products for availability.
• HDR donor constructs encoded by Adenylate cyclase 7/AC7/ADCY7 HDR Plasmid (h) and Adenylate cyclase 7/AC7/ADCY7 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ADCY7 homology arms to support homology-directed repair at defined ADCY7 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.